Lol, sorry but you happening to mention "OS" somewhere is some post doesn't mean you were predicting the current hold was due to changing OS to primary or co-primary and adding hundreds of patients.
If they are trying to do the above and regulators do not approve, then I think they will terminate the study and seek to enroll a new P3 with OS endpoint. Or just hold off and focus on Direct, also after terminating the current study. I think Linda will want to do anything but report failure. And if that means terminating and having a look at data she doesn't have to disclose, I'd say that's the choice she will make.
OS will not be SS here. Even if the vaccine worked pretty well they would need a large difference from 233 deaths in this 2:1 study, and with cross over confounding any effect on survival from the vaccine that becomes even less likely.
But the most damning proof is AV0113. A whole tumor lysate loaded DC vaccine administered to newly diagnosed GBM patients in a randomized trial. No difference in PFS or OS. How NWBO longs can just ignore those data mystifies me as much as some claiming they've been buying NWBO at $5, $3.50, $2, $1.10, and "never losing a penny." Astonishing.
The patents you keep digging up are irrelevant, but conveniently serve to confirm biases (aka "confirmation bias").
GL anyway :)
News 
Market Data 
Discover 
